Denis Moro‐Sibilot

Centre Hospitalier Universitaire de Grenoble — France

Medicine · Health Sciences

68h-index32.5kcitations635works14.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(403), Lung Cancer Research Studies(183), Lung Cancer Diagnosis and Treatment(160), Cancer Genomics and Diagnostics(93), Cancer Immunotherapy and Biomarkers(81)

Publications629 total

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Study Protocol from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Supplementary Material SM1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Supplementary Table TS1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Supplementary Figure Legends SL1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Supplementary Material SM2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
2025Open Access
Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer
ESMO Open·2025Open Access
Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable au-delà de la première ligne
Revue des Maladies Respiratoires Actualités·2025
Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable en première ligne de traitement
Revue des Maladies Respiratoires Actualités·2025
Classification des néoplasmes neuroendocrines pulmonaires et impacts sur la pratique clinique
Revue des Maladies Respiratoires Actualités·2025
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
UNC Libraries·2025Open Access
Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study
Oncology and Therapy·2025Open Access
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial
Translational Oncology·2025· 4 citedOpen Access
Response to letter Re “Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS”
European Journal of Cancer·2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS
European Journal of Cancer·2025· 4 cited
Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer
OncoImmunology·2025· 4 citedOpen Access
page 1 of 32Next →

Frequent Co-authors

Fabrice Barlési(16), Julien Mazières(16), Christian Brambilla(10), Gérard Zalcman(9), Sylvie Lantuéjoul(9), Benjamin Besse(8), Clarisse Audigier-Valette(8), Olivier Molinier(8), Élisabeth Brambilla(8), M. Pérol(8), Federico Cappuzzo(7), Éric Dansin(7), David Planchard(7), Virginie Westeel(7), Mark A. Socinski(6), Naoyuki Nogami(6), Martin Reck(6), Alexis B. Cortot(6), I. Monnet(6), B. Milleron(6)